Longitudinal lung function study in heterozygous PiMZ phenotype subjects

E. Tarjan, P. Magyar, Z. Vaczi, A. Lantos, Laszlo Vaszar

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

It is a matter of controversy whether subjects who are heterozygous (PiMZ) for alpha1-antitrypsin deficiency are at risk of developing pulmonary emphysema. To assess the role of MZ phenotype in the development of abnormal lung function the authors performed a 10 year follow-up study of 28 PiMZ subjects, compared to 28 matched-paired normal PiMM subjects. Maximal expiratory flows; and mechanical properties of the lungs were studied, in order to determine the changes of the lung function parameters characteristic of pulmonary emphysema. Total lung capacity and residual volume increased, whereas forced expiratory volume in one second, expiratory flows, diffusing capacity of the lungs for carbon monoxide, and static transpulmonary pressures decreased in the PiMZ patients. The majority of the controlled functional parameters were found to deteriorate significantly in PiMZ patients during the 10 year period. Trypsin inhibitory capacity in the PiMZ group (mean±SD) was 0.65±0.17 mg·ml-1 as compared to 1.52±0.3 mg ml-1 in the PiMM group. These changes exceeded the values expected as physiological changes due to ageing. The findings in the present longitudinal study - especially the decrease in elasticity, which is the primary pathophysiological damage in alpha1-antitrypsin deficiency - support the concept that the PiMZ phenotype is a risk factor for the development of pulmonary emphysema at younger age than in those without the deficiency.

Original languageEnglish (US)
Pages (from-to)2199-2204
Number of pages6
JournalEuropean Respiratory Journal
Volume7
Issue number12
DOIs
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

Pulmonary Emphysema
Phenotype
Lung
Lung Volume Measurements
Total Lung Capacity
Residual Volume
Elasticity
Forced Expiratory Volume
Carbon Monoxide
Trypsin
Longitudinal Studies
Pressure

Keywords

  • Follow-up
  • Intermediate alpha-antitrypsin deficiency
  • Lung function
  • PiMZ phenotype
  • Pulmonary emphysema

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Longitudinal lung function study in heterozygous PiMZ phenotype subjects. / Tarjan, E.; Magyar, P.; Vaczi, Z.; Lantos, A.; Vaszar, Laszlo.

In: European Respiratory Journal, Vol. 7, No. 12, 01.12.1994, p. 2199-2204.

Research output: Contribution to journalArticle

Tarjan, E. ; Magyar, P. ; Vaczi, Z. ; Lantos, A. ; Vaszar, Laszlo. / Longitudinal lung function study in heterozygous PiMZ phenotype subjects. In: European Respiratory Journal. 1994 ; Vol. 7, No. 12. pp. 2199-2204.
@article{6f8c1fb43fe44278a1a95e81ebea2d2b,
title = "Longitudinal lung function study in heterozygous PiMZ phenotype subjects",
abstract = "It is a matter of controversy whether subjects who are heterozygous (PiMZ) for alpha1-antitrypsin deficiency are at risk of developing pulmonary emphysema. To assess the role of MZ phenotype in the development of abnormal lung function the authors performed a 10 year follow-up study of 28 PiMZ subjects, compared to 28 matched-paired normal PiMM subjects. Maximal expiratory flows; and mechanical properties of the lungs were studied, in order to determine the changes of the lung function parameters characteristic of pulmonary emphysema. Total lung capacity and residual volume increased, whereas forced expiratory volume in one second, expiratory flows, diffusing capacity of the lungs for carbon monoxide, and static transpulmonary pressures decreased in the PiMZ patients. The majority of the controlled functional parameters were found to deteriorate significantly in PiMZ patients during the 10 year period. Trypsin inhibitory capacity in the PiMZ group (mean±SD) was 0.65±0.17 mg·ml-1 as compared to 1.52±0.3 mg ml-1 in the PiMM group. These changes exceeded the values expected as physiological changes due to ageing. The findings in the present longitudinal study - especially the decrease in elasticity, which is the primary pathophysiological damage in alpha1-antitrypsin deficiency - support the concept that the PiMZ phenotype is a risk factor for the development of pulmonary emphysema at younger age than in those without the deficiency.",
keywords = "Follow-up, Intermediate alpha-antitrypsin deficiency, Lung function, PiMZ phenotype, Pulmonary emphysema",
author = "E. Tarjan and P. Magyar and Z. Vaczi and A. Lantos and Laszlo Vaszar",
year = "1994",
month = "12",
day = "1",
doi = "10.1183/09031936.94.07122199",
language = "English (US)",
volume = "7",
pages = "2199--2204",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "12",

}

TY - JOUR

T1 - Longitudinal lung function study in heterozygous PiMZ phenotype subjects

AU - Tarjan, E.

AU - Magyar, P.

AU - Vaczi, Z.

AU - Lantos, A.

AU - Vaszar, Laszlo

PY - 1994/12/1

Y1 - 1994/12/1

N2 - It is a matter of controversy whether subjects who are heterozygous (PiMZ) for alpha1-antitrypsin deficiency are at risk of developing pulmonary emphysema. To assess the role of MZ phenotype in the development of abnormal lung function the authors performed a 10 year follow-up study of 28 PiMZ subjects, compared to 28 matched-paired normal PiMM subjects. Maximal expiratory flows; and mechanical properties of the lungs were studied, in order to determine the changes of the lung function parameters characteristic of pulmonary emphysema. Total lung capacity and residual volume increased, whereas forced expiratory volume in one second, expiratory flows, diffusing capacity of the lungs for carbon monoxide, and static transpulmonary pressures decreased in the PiMZ patients. The majority of the controlled functional parameters were found to deteriorate significantly in PiMZ patients during the 10 year period. Trypsin inhibitory capacity in the PiMZ group (mean±SD) was 0.65±0.17 mg·ml-1 as compared to 1.52±0.3 mg ml-1 in the PiMM group. These changes exceeded the values expected as physiological changes due to ageing. The findings in the present longitudinal study - especially the decrease in elasticity, which is the primary pathophysiological damage in alpha1-antitrypsin deficiency - support the concept that the PiMZ phenotype is a risk factor for the development of pulmonary emphysema at younger age than in those without the deficiency.

AB - It is a matter of controversy whether subjects who are heterozygous (PiMZ) for alpha1-antitrypsin deficiency are at risk of developing pulmonary emphysema. To assess the role of MZ phenotype in the development of abnormal lung function the authors performed a 10 year follow-up study of 28 PiMZ subjects, compared to 28 matched-paired normal PiMM subjects. Maximal expiratory flows; and mechanical properties of the lungs were studied, in order to determine the changes of the lung function parameters characteristic of pulmonary emphysema. Total lung capacity and residual volume increased, whereas forced expiratory volume in one second, expiratory flows, diffusing capacity of the lungs for carbon monoxide, and static transpulmonary pressures decreased in the PiMZ patients. The majority of the controlled functional parameters were found to deteriorate significantly in PiMZ patients during the 10 year period. Trypsin inhibitory capacity in the PiMZ group (mean±SD) was 0.65±0.17 mg·ml-1 as compared to 1.52±0.3 mg ml-1 in the PiMM group. These changes exceeded the values expected as physiological changes due to ageing. The findings in the present longitudinal study - especially the decrease in elasticity, which is the primary pathophysiological damage in alpha1-antitrypsin deficiency - support the concept that the PiMZ phenotype is a risk factor for the development of pulmonary emphysema at younger age than in those without the deficiency.

KW - Follow-up

KW - Intermediate alpha-antitrypsin deficiency

KW - Lung function

KW - PiMZ phenotype

KW - Pulmonary emphysema

UR - http://www.scopus.com/inward/record.url?scp=0028566347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028566347&partnerID=8YFLogxK

U2 - 10.1183/09031936.94.07122199

DO - 10.1183/09031936.94.07122199

M3 - Article

VL - 7

SP - 2199

EP - 2204

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 12

ER -